Skip to content
News

Sensorion to Attend Forthcoming Investor Conferences

Montpellier, France - Announcement from Business Wire:

,   and  Administrator
2 min read
Sensorion reveals its involvement in upcoming financial meetings with investors
Sensorion reveals its involvement in upcoming financial meetings with investors

Sensorion to Attend Forthcoming Investor Conferences

Sensorion, a French biotech company specializing in hearing loss disorders, will be participating in several investor conferences in September and October 2025. The company's CEO, Nawal Ouzren, and CFO, Laurene Danon, will be attending these events, and Sensorion welcomes contact via email at [email protected] for meeting requests.

Upcoming Conferences

  1. 27th Annual H.C. Wainwright Global Investment Conference, New York City, USA, September 8-10, 2025
  2. Baird 2025 Global Healthcare Conference, New York City, USA, September 9-10, 2025
  3. European Midcap Event (CF&B), Four Seasons Hôtel George V, Paris, France, September 30 and October 1, 2025
  4. Portzamparc Biotech & Health Seminar, virtual event, October 1-2, 2025
  5. Chardan's 9th Annual Genetic Medicines Conference, New York City, USA, October 21, 2025

Sensorion's Ongoing Research

Sensorion is currently conducting a Phase 1/2 clinical trial for SENS-501, aimed at correcting hereditary monogenic forms of deafness. The company is also working on SENS-401, a small molecule for the treatment and prevention of hearing loss disorders. A Phase 2 proof of concept clinical study for Cisplatin-Induced Ototoxicity is ongoing for SENS-401.

In 2024, Sensorion completed a Phase 2a study of SENS-401 in partnership with Cochlear Limited, for residual hearing preservation in patients scheduled for cochlear implantation.

About Sensorion

Sensorion is a clinical-stage biotechnology company that specializes in developing novel therapies for hearing loss disorders. The company's focus is on the genetics of hearing, with a broad strategic collaboration with the Institut Pasteur, and is working on the identification of biomarkers to improve diagnosis of hearing-related illnesses.

For more information about Sensorion, visit www.sensorion.com. For press relations, contact Ulysse Communication at [email protected] or [email protected]. For investor relations, contact [email protected].

The risks and their potential impact are detailed in Sensorion's 2024 full year report. The press release contains forward-looking statements subject to numerous risks. Recipients of this press release must comply with local laws and regulations regarding its communication. This press release does not constitute an offer to sell or subscribe for Sensorion shares in any country. The company's ISIN is FR0012596468. Sensorion's Mnemonic is ALSEN.

Read also:

Related

Latest